Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Bernthal, NM; Healey, JH; Palmerini, E; Bauer, S; Schreuder, H; Leithner, A; Martin-Broto, J; Gouin, F; Lopez-Bastida, J; Gelderblom, H; Staals, EL; Burke, ZD; Geiger, EJ; Spierenburg, G; Laeis, P; Beyerlein, E; Ye, X; van, de, Sande, M.
A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis.
J Surg Oncol. 2022; 126(8):1520-1532 Doi: 10.1002/jso.27067 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-Autor*innen der Med Uni Graz: Leithner Andreas
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND AND OBJECTIVES: Diffuse-tenosynovial giant cell tumor (D-TGCT) is a rare, locally aggressive, typically benign neoplasm affecting mainly large joints, representing a wide clinical spectrum. We provide a picture of the treatment journey of D-TGCT patients as a 2-year observational follow-up. METHODS: The TGCT Observational Platform Project registry was a multinational, multicenter, prospective observational study at tertiary sarcoma centers spanning seven European countries and two US sites. Histologically confirmed D-TGCT patients were categorized as either those who remained on initial treatment strategy (determined at baseline visit) or those who changed treatment strategy with specific changes documented (e.g., systemic treatment to surgery) at the 1-year and/or 2-year follow-up visits. RESULTS: A total of 176 patients were assessed, mean diagnosis age was 38.4 (SD ± 14.6) years; most patients had a knee tumor (120/176, 68.2%). For the 2-year observation period, most patients (75.5%) remained on the baseline treatment strategy throughout, 54/79 patients (68.4%) remained no treatment, 30/45 patients (66.7%) remained systemic treatment, 39/39 patients (100%) remained surgery. Those who changed treatment strategy utilized multimodal treatment options. CONCLUSIONS: This is the first prospectively collected analysis to describe D-TGCT patient treatments over an extended follow-up and demonstrates the need for multidisciplinary teams to determine an optimal treatment strategy.
Find related publications in this database (using NLM MeSH Indexing): Humans - administration & dosage; Adult - administration & dosage; Prospective Studies - administration & dosage; Synovitis, Pigmented Villonodular - administration & dosage; Giant Cell Tumor of Tendon Sheath - surgery, drug therapy; Knee Joint - surgery; Soft Tissue Neoplasms - pathology
Find related publications in this database (Keywords): diffuse-tenosynovial giant cell tumor (D-TGCT); pexidartinib; prospective; real-world; TGCT observational platform project (TOPP)